Sanofi closed 2025 with a sharp acceleration in Q4 performance and set a higher bar for 2026. Fourth-quarter sales rose 13.3% at constant exchange rates, lifting full-year growth to 9.9%, while business EPS climbed 26.7% in Q4 and 15.0% for the year. New product launches surged 49.4% to €1.1 billion, driven notably by Ayvakit and Altuviiio, and Dupixent delivered a strong finish with Q4 sales up 32.2% to €4.2 billion. Vaccines dipped 2.5% to €2.0 billion, despite better-than-expected influenza. The company capped the year with ten regulatory approvals across immunology and rare diseases, positive Phase 3 readouts for amlitelimab in atopic dermatitis and Dupixent in an additional inflammatory niche, and announced the pending acquisition of Dynavax alongside the completed acquisition of ViceBio. Guidance for 2026 targets high single-digit sales growth with business EPS growing slightly faster, backed by a planned €1 billion buyback.
The strategic question now is whether Sanofi is building a durable second growth pillar beyond Dupixent. The combination of amlitelimab’s Phase 3 momentum and targeted vaccine platform deals suggests a deliberate attempt to diversify growth drivers while strengthening technology control points. Dynavax brings the CpG 1018 adjuvant and commercial vaccine cash flows into the fold, potentially reshaping Sanofi’s vaccine economics and development velocity. That is a vertical integration move in a category where adjuvant access, scale, and speed can decide tenders and pandemic-readiness contracts.
For payers and HCPs, 2026 could mark a pivotal inflection in immunology care pathways. Amlitelimab’s OX40L mechanism positions it differently than IL-4/IL-13 or JAK pathways, raising real questions about sequencing, steroid-sparing strategies, and cost-offset claims in atopic dermatitis. If approved, Medical Affairs will need to establish clear patient selection frameworks and real-world evidence that distinguishes efficacy, safety, and adherence in heterogeneous, comorbid populations. For competitors with entrenched labels or recent entries, formulary dynamics and outcomes-based constructs may be the deciding factors, especially as payers re-baseline inflationary and IRA-era rebates.
The vaccine narrative is equally consequential. Q4 softness underscores cyclical pressure, but integrating Dynavax and ViceBio could recalibrate the outlook across recombinant, adjuvanted, and next-gen respiratory portfolios. Sanofi’s launch of Nuvaxovid adds breadth to COVID-19 prevention options and may serve as a platform for pricing and access strategies in a post-surge market. Control of adjuvant supply can improve gross margins and accelerate development timelines, with implications for RSV, influenza combos, and future pandemic stockpiles. Competitors reliant on third-party adjuvants will be watching manufacturing prioritization, supply security, and partnering terms.
Pipeline signals remain mixed. The tolebrutinib miss in primary progressive MS narrows the company’s near-term neurology options and raises the bar for the BTK class, where differentiation on safety and disability outcomes is tightening. Balanced against this, regulatory throughput—ten approvals, multiple Phase 3 starts, and several designations—speaks to improved execution. The agreement to lower medicine costs with the U.S. government highlights the pricing headwinds that will shape net revenue trajectories and intensify the need for head-to-head, burden-of-disease, and quality-of-life evidence.
Sanofi enters 2026 with momentum, cash flow, and a clearer platform thesis in immunology and vaccines. The forward test is whether amlitelimab can become a bona fide franchise anchor and whether adjuvant-enabled vaccine leadership can offset cyclical demand and price compression. If the Dynavax acquisition closes on schedule and label expansions land cleanly, does Sanofi emerge with two scalable growth engines—immunology and vaccines—that can sustain above-market growth beyond Dupixent’s peak years?
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
